ライフサイエンスコーパス: IUD

1 IUD malposition was an exploratory outcome.

2 IUD use at 6 months was similar between the groups: 141

3 IUDs are now considered by many experts as a first-line

4 s (subdermal implant, 45% to 78% [P < .001]; IUD, 61% to 83% [P < .001]; injection, 28% to 44% [P = .

5 bout 1 h before insertion of a Copper T 380A IUD.

6 (odds ratio [OR], 1.23; 95% CI, 1.07-1.42), IUD or implant (OR, 1.79; 95% CI, 1.28-2.48), and D&C (O

7 During the 90 days after IUD insertion, only one woman from each assignment group

8 positive urine pregnancy test 1 month after IUD insertion.

9 eeking medical care in the first month after IUD placement occurred in 5.2% of participants in the le

10 was the rate of IUD expulsion 6 months after IUD insertion; an expulsion rate 8 percentage points hig

11 -genital-tract infection is negligible after IUD insertion, with or without the administration of pro

12 ception and patient convenience to assure an IUD insertion can occur.

13 at 5 to 12 weeks of gestation who desired an IUD.

14 who were aged 50 years or younger and had an IUD insertion between Jan 1, 2001, and April 30, 2018.

15 stpartum, 53 participants (13%) never had an IUD placed and 57 (14%) were lost to follow-up.

16 118 women did not have an IUD inserted.

17 gonorrhoea or chlamydial infection having an IUD inserted have a higher risk of salpingitis than do u

18 ilar to that of infected women not having an IUD inserted.

19 lpingitis than do uninfected women having an IUD inserted; however, the risk appears similar to that

20 The 6-month rate of expulsion of an IUD after immediate insertion was higher than but not in

21 The primary outcome was selection of an IUD or implant at the clinic visit and secondary outcome

22 e presentation and agreed to placement of an IUD.

23 -based care, had higher odds of providing an IUD or implant (OR, 1.51; 95% CI, 1.19-1.91).

24 ng 575 women who underwent randomization, an IUD was inserted in 100% (258 of 258) of the women in th

25 g the 294 participants (73%) who received an IUD and completed 6-month follow-up, complete expulsion

26 (P=0.07), all in women who never received an IUD.

27 ants using DMPA injection and those using an IUD or implant, regardless of age.

28 luded women aged 50 years or younger with an IUD insertion between 2001 and 2018.

29 ted odds ratio, 1.24; 95% CI, 1.06-1.44) and IUD (adjusted odds ratio, 1.19; 95% CI, 1.06-1.32) use a

30 ine aspiration on rates of complications and IUD use are uncertain.

31 faction, uterine perforation, pregnancy, and IUD use at 6 months postpartum.

32 ]; heterogeneity chi23 = 7.3; p = 0.06), and IUDs = 1.21 (95% CI [1.14 to 1.28]; heterogeneity chi24

33 rates among users of subdermal implants and IUDs, as well as varying pregnancy and continuation rate

34 ow to counsel adolescents about implants and IUDs.

35 proach for fabricating customizable IVRs and IUDs.

36 he primary outcome for this analysis was any IUD-related uterine perforation diagnosis for the first

37 and Expulsion of Intrauterine Devices (APEX-IUD) cohort study included women aged 50 years or younge

38 Breastfeeding at IUD insertion and insertion within 36 weeks post partum

39 ed risk of perforation with breastfeeding at IUD insertion, the benefits of breastfeeding and effecti

40 non-post-partum and post-partum intervals at IUD insertion in the full cohort, and by breastfeeding s

41 non-post-partum and post-partum intervals at IUD insertion, and among post-partum individuals, to ass

42 th-care system for at least 12 months before IUD insertion.

43 We enrolled 71 non-ART (36 LNG-IUS, 31 C-IUD; 2 declined and 2 were ineligible) and 134 ART-using

44 ligible) and 134 ART-using (65 LNG-IUS, 67 C-IUD; 1 declined and 1 could not complete IUC insertion)

45 .29 to 0.10, p = 0.50) between LNG-IUS and C-IUD users.

46 (LNG-IUS) and copper intrauterine device (C-IUD) in Cape Town, South Africa.

47 IUC continuation was 78% overall; C-IUD users experienced significantly higher expulsion (8%

48 ilure and associated PID compared with the C-IUD among WLHIV.

49 gnificantly different comparing LNG-IUS to C-IUD across 6 (adjusted odds ratio [AOR]: 0.78, 95% confi

50 The primary outcome was complete IUD expulsion by 6 months postpartum; the prespecified n

51 c review I summarise the evidence concerning IUD-associated infection and infertility.

52 used transvaginal ultrasonography to confirm IUD presence and position at the 6-month postpartum foll

53 Contemporary IUDs rival tubal sterilisation in efficacy and are much

54 ciation between the previous use of a copper IUD and tubal occlusion.

55 The previous use of a copper IUD is not associated with an increased risk of tubal oc

56 t study of HIV-positive women using a copper IUD suggests that there is no significant increase in th

57 associated with the previous use of a copper IUD was 1.0 (95 percent confidence interval, 0.6 to 1.7)

58 lant, and 1.08 (95% CI, .89-1.30) for copper IUD compared with LNG implant.

59 norgestrel IUD was noninferior to the copper IUD for emergency contraception.

60 e levonorgestrel group and 300 in the copper IUD group had a 1-month urine pregnancy test.

61 el IUD group and 4.9% of those in the copper IUD group.

62 in 321 (0%; 95% CI, 0 to 1.1) in the copper IUD group; the between-group absolute difference in both

63 en assigned DMPA-IM, 13.7/100 p-y the copper IUD, and 12.7/100 p-y the LNG implant.

64 rity of the levonorgestrel IUD to the copper IUD.

65 ], .65-.97) for DMPA-IM compared with copper IUD, 0.86 (95% CI, .71-1.05) for DMPA-IM compared with L

66 Hormonal and copper IUDs have significantly different effects on the endomet

67 past use of contraceptives, including copper IUDs, previous sexual relationships, and history of geni

68 Currently, clinicians offer only copper IUDs for emergency contraception because data are lackin

69 trel IUDs and 356 assigned to receive copper IUDs, 317 and 321, respectively, received the interventi

70 users select levonorgestrel IUDs than copper IUDs for long-term contraception.

71 levonorgestrel-releasing IUDs versus copper IUDs.

72 edroxyprogesterone acetate (DMPA-IM), copper-IUD, and the levonorgestrel (LNG) implant on cervical T

73 Unlike the LNG implant or copper-IUD, DMPA-IM was associated with higher frequencies of c

74 Cu-IUD users experienced elevated BV risk that persisted th

75 Although Cu-IUD use broadly increased cervicovaginal cytokine concen

76 BV frequency was highest among Cu-IUD users at 153.6 episodes per 100 person-years (95% co

77 s were used to (1) evaluate BV risk among Cu-IUD users relative to women using no/another nonhormonal

78 n, evaluations of the association between Cu-IUD and BV have not included more than 6 months of follo

79 cts on the vaginal environment induced by Cu-IUD initiation, which may adversely impact sexual and re

80 contraceptive copper intrauterine device (Cu-IUD) may increase bacterial vaginosis (BV) risk, possibl

81 (LNG), and a copper intrauterine device (Cu-IUD) on the vaginal environment after one and six consec

82 -implant), or copper intrauterine device (Cu-IUD).

83 IUS, n = 11), copper intrauterine device (cu-IUD, n = 13) or levonorgestrel-containing combined oral

84 Among women who discontinued Cu-IUD, BV frequency was similar to pre-initiation rates wi

85 quency before, while using, and following Cu-IUD discontinuation.

86 In endometrial samples from cu-IUD users, there were no genes with statistically signif

87 In adjusted models, Cu-IUD users experienced 1.28-fold (95% CI: 1.12, 1.46) hig

88 16, 2.00) higher in the first 6 months of Cu-IUD use and remained elevated over 18 months of use (P <

89 ration of menses, a common side effect of Cu-IUD use.

90 more Th17-like cells than women using the Cu-IUD (P = .0002) or LNG implant (P = .04).

91 tivation compared to controls whereas the cu-IUD transcriptome was indistinguishable from luteal phas

92 Participants randomized to Cu-IUD exhibit elevated bacterial diversity, increased cyto

93 ter contraceptive initiation, women using Cu-IUD had increased concentrations of 25/27 cytokines comp

94 Total bacterial loads of women using Cu-IUD increase 5.5 fold after six months, predominantly dr

95 In this study of real-world data, IUD expulsion was rare but more common with immediate po

96 ver, the effects of immediate versus delayed IUD insertion after uterine aspiration on rates of compl

97 ard of an intrauterine contraceptive device (IUD).

98 l, patch, and/or ring), intrauterine device (IUD) and/or contraceptive implant, and dilation and cure

99 Intrauterine device (IUD) expulsion increases the risk of unintended pregnanc

100 the United States with intrauterine device (IUD) insertions during 2011-2018, there was no increased

101 e a convenient time for intrauterine device (IUD) placement; the placement could then coincide with e

102 before insertion of an intrauterine device (IUD) remains uncertain.

103 However, intrauterine device (IUD) use has increasingly replaced OC use.

104 the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs f

105 A), implant, pills, and intrauterine device (IUD)) were promoted and provided to women not using a re

106 thods-DMPA-IM, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant-on human immuno

107 nthly dispensations of intrauterine devices (IUDs) and oral contraceptive pills (OCPs) per 1000 femal

108 methods, which include intrauterine devices (IUDs) and subdermal hormonal implants, are used by only

109 eptive methods include intrauterine devices (IUDs) and subdermal implants and show great promise for

110 raceptive implants and intrauterine devices (IUDs) are long-acting reversible contraceptives (LARCs)

111 ptive effectiveness of intrauterine devices (IUDs) has been attributed in part to a foreign body reac

112 w discusses the use of intrauterine devices (IUDs) in United States teens as a potential strategy to

113 ration risk related to intrauterine devices (IUDs) inserted immediately post partum and among non-pos

114 t infection related to intrauterine devices (IUDs) limits their wider use.

115 lling and insertion of intrauterine devices (IUDs) or progestin implants and 20 to provide standard c

116 Intrauterine devices (IUDs) provide highly effective, reversible, long-term co

117 contraception (LARC), intrauterine devices (IUDs), implants, short-acting hormonal injection, and ba

118 avaginal rings (IVRs), intrauterine devices (IUDs), injectables and subdermal implants.

119 Previous studies of intrauterine devices (IUDs), many of which are no longer in use, suggested tha

120 tives (LARCs), such as intrauterine devices (IUDs).

121 oral contraception, or intrauterine devices (IUDs).

122 progestagen-releasing intrauterine devices (IUDs): ORs = 1.23 (95% CI [1.14 to 1.32]; p < 0.001), 1.

123 us injectable/implants/intrauterine devices [IUDs] 18%; p = 0.06).

124 ersible contraception (intrauterine devices [IUDs] and implants) with other commonly prescribed contr

125 Early IUD placement at 2 to 4 weeks postpartum compared with 6

126 ants were randomly assigned to undergo early IUD placement and 201 to undergo interval IUD placement

127 condary outcomes were partial IUD expulsion, IUD removal, pelvic infection, patient satisfaction, ute

128 uterine perforation diagnosis for the first IUD insertion in this time period.

129 ing should be based on individual desire for IUD contraception and patient convenience to assure an I

130 was a significant increase in the level for IUDs of 0.64 (95% CI, 0.02-1.26) and for OCPs of 13.2 (9

131 and a significant decrease in the level for IUDs of 0.82 (95% CI, -1.55 to -0.09) after OHIP- in Ont

132 the likelihood that a woman would retain her IUD at 90 days or the frequency of postinsertion medical

133 No statistically significant changes in IUD or OCP dispensations were observed in areas with hig

134 rison group, overdiagnosis of salpingitis in IUD users, and inability to control for the confounding

135 P+, there was an immediate level increase in IUDs dispensed to Ontario females aged 15 to 24 years (i

136 3.6 to 4.4) with every 5 years since initial IUD use (P-trend = .03), while CRP increased an average

137 ly IUD placement and 201 to undergo interval IUD placement (mean [SD] age, 29.9 [5.4] years; 46 [11.4

138 acking on the efficacy of the levonorgestrel IUD for this purpose.

139 n 5.2% of participants in the levonorgestrel IUD group and 4.9% of those in the copper IUD group.

140 ith the noninferiority of the levonorgestrel IUD to the copper IUD.

141 The levonorgestrel IUD was noninferior to the copper IUD for emergency cont

142 randomly assigned to receive levonorgestrel IUDs and 356 assigned to receive copper IUDs, 317 and 32

143 ine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception.

144 LNG-IUD and, to a lesser extent, DMPA use were associated wi

145 5 expression were observed with DMPA and LNG-IUD use (P < .01 for all comparisons).

146 orgestrel-releasing intrauterine device (LNG-IUD; n = 27), oral contraceptive pills (n = 32), or no h

147 The use of LNG-IUD increased the proportion of CD4(+) and CD8(+) T cell

148 orgestrel-releasing intrauterine system (LNG-IUD), gonadotropin-releasing hormone analogues (GnRHa; n

149 1:1 ratio to receive a levonorgestrel 52-mg IUD or a copper T380A IUD.

150 cts an understanding of the safety of modern IUDs, the potential for this highly effective method to

151 Most IUDs were levonorgestrel-releasing (259 234 [79.4%]).

152 orical concerns regarding the association of IUD and infection; however, modern studies have shown th

153 lity was not associated with the duration of IUD use, the reason for the removal of the IUD, or the p

154 ir evidence indicates no important effect of IUD use on tubal infertility.

155 The 5-year cumulative incidence of IUD expulsion was highest for insertions 0 to 3 days pos

156 The primary outcome was the rate of IUD expulsion 6 months after IUD insertion; an expulsion

157 The rate of IUD removal for any reason other than partial expulsion

158 whether such prophylaxis reduces the rate of IUD removal within 90 days.

159 ediate insertion resulted in higher rates of IUD use at 6 months, without an increased risk of compli

160 Six-month rates of IUD use were higher in the immediate-insertion group (92

161 es was to compare the incidence and risks of IUD-related uterine perforations by non-post-partum and

162 Timing of IUD insertion post partum was categorized into discrete

163 ns make informed choices about the timing of IUD placement.

164 reaction as a common mechanism of action of IUDs.

165 y, eliminate user error, and, in the case of IUDs, have extremely low or no systemic drug absorption.

166 f 1344 participants, increases in the use of IUDs in South Carolina were noted after the implementati

167 Use of IUDs increased in South Carolina (95 [14.0%] to 114 [17.

168 trol sites reported receiving counselling on IUDs or implants (565 [71%] of 797 vs 271 [39%] of 693,

169 Both complete and partial IUD-related perforations were identified.

170 Secondary outcomes were partial IUD expulsion, IUD removal, pelvic infection, patient sa

171 djusted HRs using women with non-post partum IUD insertion as the referent were 5.34 (95% CI, 4.47-6.

172 28 days) or interval (42-56 days) postpartum IUD placement.

173 Early postpartum IUD placement, at 2 to 4 weeks postpartum, vs standard i

174 intended pregnancy; how timing of postpartum IUD insertion and breastfeeding are associated with risk

175 s [61.1%]), with lower proportions providing IUD or implant (4059 physicians [18.5%]) and D&C (152 ph

176 Recently, IUDs have become a recommended contraceptive option for

177 t HIV diagnosis for levonorgestrel-releasing IUDs versus copper IUDs.

178 hern California enrolled women who requested IUD insertion and were at low risk of sexually transmitt

179 Our results suggest IUD use and tubal ligation are not associated with highe

180 a levonorgestrel 52-mg IUD or a copper T380A IUD.

181 The concern that IUDs that contain copper--currently the most commonly us

182 Current data do not support that IUDs affect long-term fertility or increase sexually tra

183 f IUD use, the reason for the removal of the IUD, or the presence or absence of gynecologic problems

184 Traditionally, the IUD was not thought of as an appropriate teen contracept

185 Therefore, IUD insertion timing should be based on individual desir

186 s were randomly assigned (in a 5:6 ratio) to IUD insertion immediately after the procedure or 2 to 6

187 ease, we examined the association of OC use, IUD use, and tubal ligation with plasma levels of C-reac

188 luated to alleviate the pain associated with IUD insertion.

189 though the risk for uterine perforation with IUD insertion 4 days to 6 weeks or less post partum is n